Endocrinology · Metabolic Health · Internal Medicine · June 2026
A comprehensive, medically reviewed reference on oxandrolone (Oxandrin) — covering its pharmacology, FDA-approved indications for weight restoration and catabolic states, how it compares to other anabolic agents, critical safety information, and legal access for patients in the United States and internationally.
| Generic Name | Oxandrolone |
| Brand Name | Oxandrin |
| Drug Class | Synthetic anabolic androgenic steroid (AAS), 17-alpha-alkylated testosterone derivative |
| FDA Approvals | 1964, original approval; current indications reaffirmed through subsequent label updates |
| DEA Schedule | Schedule III controlled substance |
| Available Doses | 2.5 mg · 10 mg tablets |
| Standard Adult Dose | 2.5–20 mg per day, in divided doses, for 2 to 4 weeks per course |
| Onset of Clinical Effect | Weight gain typically assessed over a 2–4 week treatment course |
| Half-Life | ~9–10 hours |
| Anabolic:Androgenic Ratio | Favorable relative to testosterone, contributing to its use in clinical wasting states, though androgenic effects still occur |
| Boxed Warning | Hepatotoxicity — peliosis hepatis and hepatic neoplasms associated with 17-alpha-alkylated steroids |
| Generic Available | Yes — oxandrolone is widely available in generic form |
Oxandrolone, marketed under the brand name Oxandrin, is a synthetic anabolic androgenic steroid derived from testosterone, first approved by the U.S. Food and Drug Administration in 1964. It is prescribed as adjunctive therapy to promote weight gain following significant weight loss due to extensive surgery, chronic infection, or severe trauma, and in certain patients who fail to gain or maintain weight for reasons that are not otherwise explained. It is also used to offset the protein breakdown associated with prolonged corticosteroid therapy and, in some clinical settings, to help relieve bone pain associated with osteoporosis.
Oxandrolone was specifically developed to have a more favorable ratio of anabolic (tissue-building) to androgenic (masculinizing) activity than testosterone itself, which is the pharmacological rationale for its use in clinical wasting and catabolic conditions rather than as a direct testosterone replacement. It remains subject to virilizing and androgenic side effects, and its classification as a Schedule III controlled substance in the United States reflects both its legitimate medical utility and its recognized potential for non-medical misuse, particularly in athletic and bodybuilding contexts, which falls entirely outside its approved medical use and carries serious health risks.
Oxandrolone is available in generic form and is typically prescribed for defined, short courses rather than continuous long-term use, reflecting both its therapeutic goal — restoring weight and reversing catabolism over a discrete treatment period — and its recognized hepatic and metabolic risk profile, discussed in detail below.
Oxandrolone binds to androgen receptors in skeletal muscle, bone, and other tissues, promoting protein synthesis and nitrogen retention. This anabolic activity increases lean tissue accretion and can reverse the net protein catabolism seen in severe illness, major surgery, chronic infection, and prolonged corticosteroid exposure, all of which shift the body toward a catabolic, muscle-wasting state. By binding the same androgen receptor pathway used by endogenous testosterone, but with structural modifications that favor anabolic over androgenic receptor activity in target tissues, oxandrolone is able to produce meaningful weight and lean mass restoration with a comparatively lower androgenic burden than testosterone at clinically effective doses — though androgenic effects, particularly virilization in female patients, remain a recognized risk.
Oxandrolone is a 17-alpha-alkylated steroid, a structural modification that allows the molecule to resist first-pass hepatic metabolism and remain orally bioavailable. This same modification is directly responsible for the hepatotoxicity risk that distinguishes oral 17-alpha-alkylated anabolic steroids, including oxandrolone, from non-alkylated injectable anabolic agents, and is the basis for the boxed hepatic warning discussed later in this guide.
| Feature | Oxandrolone (Oxandrin) | Oxymetholone (Anadrol-50) | Testosterone (various) | Nandrolone (Deca-Durabolin) |
|---|---|---|---|---|
| Route | Oral | Oral | Injectable, topical, other | Injectable |
| 17-Alpha-Alkylated | Yes | Yes | No | No |
| Primary Approved Use | Weight restoration, catabolic states | Certain anemias (bone marrow stimulation) | Male hypogonadism, testosterone deficiency | Certain anemias (less commonly used today) |
| Relative Androgenic Effect | Lower | Moderate | Reference standard | Lower |
| Hepatotoxicity Risk | Present (boxed warning) | Present (boxed warning), generally considered higher | Low (non-alkylated routes) | Low (non-alkylated, injectable) |
| DEA Schedule | Schedule III | Schedule III | Schedule III | Schedule III |
Oxandrolone's comparatively favorable anabolic-to-androgenic ratio and generally milder side effect profile relative to oxymetholone have made it a frequently chosen agent for weight restoration therapy, particularly in patients for whom minimizing virilizing and hepatic risk is a priority, including women and pediatric patients under specialist supervision. Testosterone and nandrolone remain relevant comparators for their respective approved indications rather than direct substitutes, since each of these agents serves a distinct primary clinical purpose. The choice of anabolic agent is always individualized and made by a physician familiar with the patient's specific diagnosis, hepatic status, and treatment goals.
Oxandrolone is FDA-approved as adjunctive therapy to promote weight gain following weight loss caused by extensive surgery, chronic infections, or severe trauma, and for certain patients who, without a definable pathophysiologic reason, fail to gain or maintain normal weight. It is used alongside adequate nutritional support rather than as a substitute for it, with the goal of reversing a catabolic state and restoring lean body mass over a defined treatment course.
Long-term corticosteroid therapy, used to manage a range of chronic inflammatory and autoimmune conditions, produces significant protein catabolism as a known side effect. Oxandrolone is FDA-approved to help offset this corticosteroid-induced protein breakdown, supporting the maintenance of lean tissue in patients who require prolonged corticosteroid treatment.
Oxandrolone is FDA-approved for the relief of bone pain associated with osteoporosis, used as part of a broader osteoporosis management plan that may include calcium, vitamin D, and other bone-directed therapies, under specialist guidance.
Oxandrolone is available in 2.5 mg and 10 mg tablets. Dosing is individualized to the indication, patient sex, and clinical response, and courses are typically limited to a defined duration rather than continuous indefinite use.
| Adult Men — Weight Restoration | 5–10 mg two to four times daily (total approximately 20 mg/day), for a course of 2 to 4 weeks. May be repeated intermittently as clinically indicated. |
| Adult Women — Weight Restoration | 2.5–20 mg per day in divided doses, generally at the lower end of the range given increased sensitivity to virilizing effects. Course duration and repetition individualized by the prescriber. |
| Corticosteroid-Associated Catabolism | Dose individualized based on clinical response, generally within the same 2.5–20 mg/day range used for weight restoration. |
| Pediatric Use | Requires specialist supervision, typically endocrinology, with careful monitoring of bone age and growth given the risk of accelerated epiphyseal (growth plate) maturation. |
| Elderly Patients | Use with caution; individualized dosing, considering hepatic and prostate status. |
| Hepatic Impairment | Use is generally avoided or approached with extreme caution given oxandrolone's hepatic metabolism and known hepatotoxicity risk. |
Oxandrolone therapy is generally structured around defined, time-limited courses with reassessment of ongoing need, rather than open-ended daily use. This approach reflects both the therapeutic goal of restoring a specific weight or lean mass deficit and the importance of limiting cumulative hepatic and metabolic exposure. Any continuation beyond an initial course should be a deliberate decision made with the prescribing physician based on documented clinical benefit.
Oxandrolone is generally taken in divided doses throughout the day, with or without food, according to the specific schedule provided by the prescribing physician. Tablets should be swallowed whole with water.
Adequate caloric and protein intake is an essential companion to oxandrolone therapy for weight restoration; the medication supports anabolic processes but does not substitute for the nutritional building blocks the body needs to rebuild lean tissue. Patients should follow any concurrent nutritional guidance provided alongside their prescription.
Periodic laboratory monitoring, including liver function tests and lipid panels, is a standard part of oxandrolone therapy given the drug's known hepatic and lipid effects, and patients should attend all scheduled follow-up appointments and lab draws for the duration of treatment.
Oxandrolone's side effect profile reflects its androgenic and anabolic activity, its hepatic metabolism, and its effect on lipid parameters. Side effects vary meaningfully by sex, dose, and duration of use.
Fluid retention and mild edema are commonly reported, reflecting oxandrolone's effect on sodium and water retention. Acne and other androgen-related skin changes may occur. Changes in libido, in either direction, have been reported by both men and women. Nausea and mild gastrointestinal upset are also reported by some patients.
In women, virilizing effects — including voice deepening, increased facial or body hair growth, clitoral enlargement, and menstrual irregularities — are a recognized dose-related risk and may not fully reverse even after stopping the medication if allowed to progress; any early signs of virilization should be reported to the prescriber promptly so the dose can be reassessed. In men, oxandrolone can suppress natural testosterone production during use, and gynecomastia (breast tissue enlargement) has been reported in some patients.
Oxandrolone, as a 17-alpha-alkylated anabolic steroid, carries an FDA boxed warning for hepatotoxicity. Reported hepatic effects include peliosis hepatis (blood-filled cysts within the liver, which can rupture and cause life-threatening hemorrhage), cholestatic jaundice, and, with long-term use, benign and malignant hepatic tumors including hepatocellular carcinoma. These hepatic effects may not be preceded by any warning signs or abnormal liver function tests, and can persist or continue to progress even after the medication is discontinued. Regular liver function monitoring is standard practice during treatment, and any new abdominal pain, unexplained fatigue, dark urine, or jaundice (yellowing of the skin or eyes) requires prompt medical evaluation.
Oxandrolone can significantly lower HDL ("good") cholesterol and raise LDL ("bad") cholesterol, an adverse lipid profile shift that, with prolonged use, may increase cardiovascular risk. Lipid panels should be monitored periodically during treatment, particularly in patients with pre-existing cardiovascular risk factors.
In pediatric patients, oxandrolone can accelerate bone maturation without a proportional increase in linear growth, potentially resulting in a shorter final adult height if growth plates close prematurely. Periodic bone age assessment (typically every 6 months) is standard practice in pediatric patients receiving oxandrolone therapy under specialist supervision.
Anabolic steroids, including oxandrolone, may stimulate the growth of existing prostate tissue and are contraindicated in men with known or suspected prostate cancer. Periodic prostate evaluation is advisable in older men receiving extended treatment.
Oxandrolone's Schedule III controlled substance status reflects a recognized potential for non-medical misuse, particularly for physique or performance enhancement outside any diagnosed medical condition. Use outside a valid prescription and legitimate medical indication carries the same hepatic, cardiovascular, and endocrine risks described in this guide, often at doses and durations well outside those studied for safety, and is not a use this guide supports or provides direction for.
| Interaction | Mechanism | Clinical Consequence | Management |
|---|---|---|---|
| Warfarin and other anticoagulants | Oxandrolone potentiates anticoagulant effect, mechanism not fully established | Increased bleeding risk; significant INR elevation reported | Anticoagulant dose reduction and closer INR monitoring are typically required; disclose all anticoagulant use to the prescriber. |
| Insulin and oral antidiabetic medications | Anabolic steroids may improve glucose tolerance | Reduced insulin or antidiabetic medication requirement, risk of hypoglycemia if doses are not adjusted | Monitor blood glucose closely; antidiabetic medication doses may need to be reduced under physician guidance. |
| Corticosteroids | Additive fluid-retaining effect | Increased risk of edema | Monitor for fluid retention, particularly in patients with cardiac or renal impairment. |
| Other hepatotoxic medications | Additive hepatic burden | Increased risk of liver injury | Disclose all medications to the prescriber; more frequent liver function monitoring may be warranted. |
Severe abdominal pain, yellowing of the skin or eyes, dark urine, unusual fatigue, or unexplained bruising or bleeding during oxandrolone treatment should be treated as a potential medical emergency. Seek prompt medical evaluation and stop the medication until assessed.
Known or suspected prostate cancer, or male breast cancer: Contraindicated given the potential for androgen-sensitive tumor stimulation.
Pregnancy: Contraindicated due to the risk of virilization of a female fetus.
Severe hepatic, renal, or cardiac disease: Use is generally avoided given the fluid retention and hepatic metabolism associated with oxandrolone.
Known hypersensitivity: Contraindicated in patients with a prior hypersensitivity reaction to oxandrolone or its components.
Hypercalcemia: Anabolic steroids can increase calcium levels, particularly in patients with breast cancer and bone metastases; use requires close monitoring in this setting.
Pediatric patients: Use requires specialist supervision given the risk of accelerated bone maturation and effects on final adult height.
Attend all scheduled liver function and lipid monitoring appointments. Hepatic changes associated with oxandrolone may not produce early symptoms, making laboratory monitoring an essential safety measure rather than an optional formality.
Report any signs of virilization promptly if you are a woman taking oxandrolone. Early recognition and dose adjustment reduce the likelihood of effects that may not fully reverse after stopping the medication.
Maintain adequate nutrition throughout treatment. Oxandrolone supports anabolic processes but requires sufficient dietary protein and calories to achieve its intended weight-restoration effect.
Complete only the course prescribed, and discuss any perceived need for continuation or repeat courses with your physician rather than self-extending treatment.
Never use oxandrolone obtained outside a valid prescription or for a purpose other than the one your physician has diagnosed and is treating; doing so removes the medical monitoring that meaningfully reduces this medication's most serious risks.
Store at room temperature (20–25°C / 68–77°F), away from moisture, heat, and light, and out of reach of children. As a Schedule III controlled substance, oxandrolone should never be shared.
In the United States, oxandrolone is a prescription medication classified as a Schedule III controlled substance, available from any licensed pharmacy following a physician consultation and an appropriate clinical diagnosis, such as a documented wasting condition, corticosteroid-associated catabolism, or osteoporosis-related bone pain. Generic oxandrolone is widely available and typically prescribed with defined treatment courses and follow-up laboratory monitoring built into the care plan.
Given oxandrolone's Schedule III status and hepatic monitoring requirements, prescribing typically involves an in-person or telehealth evaluation with a physician who can establish an appropriate diagnosis, order baseline and follow-up laboratory testing, and monitor for the specific risks outlined in this guide.
Internationally, oxandrolone is a controlled or prescription-only medication in most major healthcare markets. The same standard for legitimate pharmacy sourcing applies universally: a mandatory prescription requirement tied to a genuine medical diagnosis, a verifiable pharmacy license, transparent pricing, and accountable dispensing records. Anabolic steroids, including oxandrolone, are among the medications most frequently diverted to unregulated markets for non-medical use; sourcing from unlicensed vendors carries substantial risk, including counterfeit, mislabeled, or contaminated products.
My Online Med Shop provides genuine, verified oxandrolone sourced exclusively from verified pharmaceutical manufacturers, dispensed strictly against a valid prescription and documented medical diagnosis, with secure encrypted checkout, discreet packaging, and 24/7 customer support available for every order.
Oxandrolone is FDA-approved as adjunctive therapy to promote weight gain after significant weight loss from major surgery, chronic infection, or severe trauma; to offset the protein breakdown caused by prolonged corticosteroid use; and for the relief of bone pain associated with osteoporosis. It is prescribed for these defined clinical indications, always alongside adequate nutrition and monitoring, rather than as a general-purpose muscle-building supplement.
Oxandrolone is a 17-alpha-alkylated steroid, a structural feature that allows it to survive first-pass liver metabolism and be taken orally, but that same feature is associated with hepatotoxicity, including peliosis hepatis and, with prolonged use, hepatic tumors. This is a class effect of oral 17-alpha-alkylated anabolic steroids and is the basis for the FDA boxed warning and the routine liver function monitoring built into oxandrolone treatment.
Oxandrolone is used in female patients for its approved indications, generally at the lower end of the dosing range given increased sensitivity to virilizing effects such as voice deepening, facial or body hair growth, and clitoral enlargement. Close monitoring for early signs of virilization is an important part of safe use in women, since some virilizing effects may not fully reverse if the medication is continued after they appear.
Oxandrolone is chemically an anabolic androgenic steroid and is one of the agents sometimes diverted for non-medical physique or performance use, which is why it is a Schedule III controlled substance. Its FDA-approved medical use is specifically for weight restoration in wasting conditions, corticosteroid-associated catabolism, and osteoporotic bone pain, under physician supervision with defined dosing and laboratory monitoring — a very different context from unsupervised non-medical use, which carries the same hepatic, cardiovascular, and endocrine risks, often at higher doses and for longer durations than have been studied for safety.
Oxandrolone for weight restoration is typically prescribed in courses of 2 to 4 weeks, which may be repeated intermittently based on clinical response and ongoing need, as determined by the prescribing physician. It is not generally intended for continuous, indefinite daily use, reflecting both its therapeutic design and the importance of limiting cumulative hepatic exposure.
Standard monitoring includes periodic liver function tests and lipid panels, given oxandrolone's known hepatotoxicity and cholesterol effects. In pediatric patients, periodic bone age assessment is also standard, given the risk of accelerated growth plate closure. Patients should attend all scheduled monitoring appointments for the duration of treatment.
Yes. Oxandrolone can significantly lower HDL ("good") cholesterol and raise LDL ("bad") cholesterol, an adverse shift in lipid profile that is monitored during treatment, particularly in patients with existing cardiovascular risk factors. This effect is one of the reasons treatment courses are generally kept as short as clinically appropriate.
Oxandrolone (Oxandrin) fills a specific and long-established clinical role in restoring weight and reversing protein catabolism in patients recovering from major surgery, chronic infection, severe trauma, or prolonged corticosteroid therapy, as well as in relieving bone pain associated with osteoporosis. Its comparatively favorable anabolic-to-androgenic profile relative to older anabolic agents has made it a preferred choice in several of these clinical scenarios, particularly when minimizing virilizing effects is a priority.
As a 17-alpha-alkylated oral anabolic steroid, oxandrolone carries a boxed FDA warning for hepatotoxicity, along with recognized effects on lipid parameters, growth in pediatric patients, and androgenic changes, all of which require structured monitoring and a defined, physician-guided treatment course rather than open-ended use.
Within the parameters of a valid prescription, an appropriate diagnosis, consistent laboratory monitoring, and verified pharmaceutical sourcing, oxandrolone has a long clinical track record as an effective, closely supervised tool for weight restoration and catabolic states, distinct from and not a substitute for its non-medical, unsupervised use in other contexts.
Buy Oxycodone Online USA: Uses, Dosage & Safety Guide 2026
Buy Oxandrolone Online USA: Uses, Dosage & Safety Guide 2026
Buy Anadrol-50 Online USA: Uses, Dosage & Safety Guide 2026
Buy Escitalopram Online USA: Uses, Dosage & Safety Guide 2026